Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes throu...
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Aligos Therapeutics (NASDAQ:ALGS) with a Buy and maintains $5...
HC Wainwright & Co. analyst Patrick R. Trucchio assumes Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and announce...
Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(1.53) per share which beat the analyst consensus estimate of $...
Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(2.11) per share which beat the analyst consensus estimate of $...
